论文部分内容阅读
[目的]系统评价根治性放疗与根治性手术治疗膀胱癌临床效果。[方法]应用END-NOTE软件全面检索Pubmed(1973～2013年)数据库,对符合纳入标准的临床对照试验,采用RevMan4.3软件进行Meta分析。对于无对照临床研究资料,采用同质合并分析。[结果]共纳入6个临床对照试验,共1264例患者,Meta分析结果显示,根治性放疗与根治性手术切除治疗膀胱癌患者的5年生存率无统计学差异(P=0.36),合并比值比(OR)为1.10(95%CI:0.86～1.40)。18篇无对照临床研究共纳入根治性放疗治疗膀胱癌患者1749例,多数文献采用全膀胱放疗40～60Gy,联合以顺铂为基础的化疗方案,完全反应率达到65%以上,平均5年总生存率在50%以上,最低为37%,最高可达82%。[结论]根治性放疗不会降低膀胱癌患者生存率,且能维持正常膀胱功能,提高了患者生存质量。
[Objective] To systematically evaluate the clinical effect of radical radiotherapy and radical surgery on bladder cancer. [Methods] Pubmed database (1973-2013) was searched comprehensively with END-NOTE software. Meta-analysis was performed using RevMan 4.3 software in clinical controlled trials that met the inclusion criteria. For uncontrolled clinical study data, homogenous pool analysis was used. [Results] A total of 6 clinical control trials were enrolled in this study. A total of 1264 patients were included in the study. Meta-analysis showed that there was no significant difference in 5-year survival rates between radical radiotherapy and radical surgical resection for bladder cancer (P = 0.36) The odds ratio (OR) was 1.10 (95% CI: 0.86 to 1.40). Eighteen uncontrolled clinical trials included 1749 cases of bladder cancer treated with radical radiotherapy. Most of the articles used total bladder radiotherapy 40-60 Gy. Combined with cisplatin-based chemotherapy, the complete response rate was over 65% with an average of 5 years Survival in more than 50%, a minimum of 37%, up to 82%. [Conclusion] Radical radiotherapy can not reduce the survival rate of patients with bladder cancer, and can maintain normal bladder function, improve the quality of life of patients.